These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 3665205)
1. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test. Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205 [TBL] [Abstract][Full Text] [Related]
2. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky IB; Foley J; Nelson P; Goodman WG N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. McCarthy JT; Milliner DS; Johnson WJ Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295 [TBL] [Abstract][Full Text] [Related]
4. Desferrioxamine in the treatment of aluminum overload. Ackrill P; Day JP Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106 [TBL] [Abstract][Full Text] [Related]
5. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006 [No Abstract] [Full Text] [Related]
6. [Bone disorders in children with chronic renal insufficiency exposed to high ingestion of aluminum]. Gordillo-Paniagua G; Valencia-Mayoral P; Mercado L; Medina-Mercado M Bol Med Hosp Infant Mex; 1990 May; 47(5):336-41. PubMed ID: 2390188 [TBL] [Abstract][Full Text] [Related]
7. [Hypercalcemia and hyperaluminemia in children with chronic renal insufficiency]. Hinojosa-Lezama M; Gordillo-Paniagua G; Muñoz-Arizpe R; Mercado-Polo L Bol Med Hosp Infant Mex; 1987 Sep; 44(9):535-9. PubMed ID: 3663320 [No Abstract] [Full Text] [Related]
8. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597 [TBL] [Abstract][Full Text] [Related]
9. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine. Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925 [No Abstract] [Full Text] [Related]
10. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553 [TBL] [Abstract][Full Text] [Related]
11. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine. Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276 [TBL] [Abstract][Full Text] [Related]
12. Low serum aluminum values in dialysis patients with increased bone aluminum levels. van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776 [TBL] [Abstract][Full Text] [Related]
13. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis]. de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604 [No Abstract] [Full Text] [Related]
14. Prevention and treatment of aluminum intoxication in chronic renal failure. Simon P; Allain P; Ang KS; Cam G; Mauras Y Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543 [No Abstract] [Full Text] [Related]
15. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion. Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504 [No Abstract] [Full Text] [Related]
16. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis. Graf H; Stummvoll HK; Meisinger V Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995 [TBL] [Abstract][Full Text] [Related]
17. Improvement of anaemia with desferrioxamine in haemodialysis patients. Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265 [TBL] [Abstract][Full Text] [Related]
18. [Detecting and evaluating hyperaluminemia in 3 dialysis centers]. Balabán D; Simícková J; Kubátko J; Syrovátka P Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999 [TBL] [Abstract][Full Text] [Related]
19. Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids. Rovelli E; Luciani L; Pagani C; Albonico C; Colleoni N; D'Amico G Clin Nephrol; 1988 Jun; 29(6):294-8. PubMed ID: 3396232 [TBL] [Abstract][Full Text] [Related]
20. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis]. Wang G; Zhu P; Wang S Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]